Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.PHILADELPHIA, Pennsylvania — Treatment with aprocitentan, a novel agent currently under Food and Drug Administration review for lowering blood pressure in people with treatment-resistant hypertension, showed efficacy and safety in people with stage 3 or 4The findings provide support for potentially using aprocitentan, if approved for U.S.
Among the small number of people with stage 4 CKD, the incremental nighttime systolic blood pressure on aprocitentan, compared with placebo, was even greater, with about a 15 mm Hg incremental reduction on 12.5 mg daily and about a 17 mm Hg incremental reduction on the higher dose. "Fluid retention is an issue with aprocitentan," Bakris acknowledged. But he also highlighted than only 6 of the 162 patients with CKD required hospitalization forduring the study, and one of these cases had placebo treatment. Among the five with acute heart failure while on aprocitentan, none had to stop their treatment, and two had a clear prior history of heart failure.
Endothelin has a potent vasoconstrictive effect and is"implicated in the pathogenesis of hypertension," Bakris explained. Aprocitentan antagonizes both the endothelin A and B receptors.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: physorg_com - 🏆 388. / 55 Read more »